The state of Indiana currently has 7 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Rostock International Parkinson's Disease Study (ROPAD)
Recruiting
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
03/21/2024
Locations: Indiana University, Department of Neurology, Indianapolis, Indiana
Conditions: ParkinsonĀ“s Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
03/21/2024
Locations: Pd0060 50595, Indianapolis, Indiana
Conditions: Parkinson Disease
Registry of Deep Brain Stimulation With the VERCISEā„¢ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Methodist Hospital of Indianapolis, Indianapolis, Indiana
Conditions: Parkinson's Disease
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Parkinson's Disease
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Recruiting
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Gender:
All
Ages:
All
Trial Updated:
05/26/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
Robotic Gait Rehabilitation in Parkinson's Disease
Recruiting
The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes. Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: IU Health Neurorehabilitation and Robotics, Indianapolis, Indiana
Conditions: Parkinson Disease, Gait Disorder, Sensorimotor
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias